# Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)

> **NCT00642746** · PHASE2 · TERMINATED · sponsor: **OHSU Knight Cancer Institute** · enrollment: 16 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Erlotinib
- **DRUG:** Fluorouracil
- **DRUG:** Leucovorin
- **DRUG:** Oxaliplatin
- **DRUG:** Irinotecan

## Key facts

- **NCT ID:** NCT00642746
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-03
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** Terminated due to poor enrollment and grade 3 toxicities noted during an interim analysis.
- **Last updated:** 2014-09-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00642746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00642746, "Erlotinib and Chemotherapy for 2nd Line Treatment (Tx) of Metastatic Colorectal Cancer (mCRC)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00642746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*